<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3-5614-21
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LATUDA 80 MG F.C.TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LURASIDONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        80
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store below 30°C ,  protect from Light
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        243.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Bushu Pharmaceuticals Ltd. " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Bushu Pharmaceuticals Ltd. 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Medius AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AE05 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Latuda </strong><strong>is and what it is used for</strong></p><p>&nbsp;</p><p>Latuda contains the active substance lurasidone and belongs to a group of medicines called antipsychotics. It is used to treat symptoms of schizophrenia in adults aged 18&nbsp;years or over. Lurasidone works by blocking receptors in the brain to which the substances dopamine and serotonin attach. Dopamine and serotonin are neurotransmitters (substances that allow nerve cells to communicate with each other) that are involved in the symptoms of schizophrenia. By blocking their receptors, lurasidone helps to normalise the activity of the brain, reducing the symptoms of schizophrenia.</p><p>&nbsp;</p><p>Schizophrenia is a disorder with symptoms such as hearing things, seeing or sensing things that are not there, mistaken beliefs, unusual suspiciousness, becoming withdrawn, incoherent speech and behaviour and emotional flatness. People with this disorder may also feel depressed, anxious, guilty, or tense. This medicine is used to improve your symptoms of schizophrenia.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do NOT take Latuda if you:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are allergic to lurasidone or any of the other ingredients of this medicine (listed in section 6)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking medicines which may affect the level of lurasidone in your blood such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for fungal infections such as itraconazole, ketoconazole (except as a shampoo), posaconazole or voriconazole</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for an infection such as the antibiotic clarithromycin or telithromycin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for HIV infections such as cobicistat, indinavir, nelfinavir, ritonavir, and saquinavir</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; boceprevir, and telaprevir (medicines for chronic hepatitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nefazodone (a medicine for depression)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin (a medicine for tuberculosis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carbamazepine, phenobarbital and phenytoin (medicines for seizures)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St John&rsquo;s wort (<em>Hypericum perforatum</em>) (herbal medicine for depression).</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>It may take several days or even weeks before this medicine will have a full effect. Contact your doctor if you have questions on this medicine.</p><p>&nbsp;</p><p>Talk to your doctor or pharmacist before taking this medicine, or during treatment, especially if you have:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Parkinson&rsquo;s disease or dementia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ever been diagnosed with a condition whose symptoms include high temperature and muscle stiffness (also known as neuroleptic malignant syndrome) or if you have ever experienced rigidity, tremors or problems moving (extrapyramidal symptoms) or abnormal movements of the tongue or face (tardive dyskinesia). You should be aware that these conditions may be caused by this medicine<strong><em> </em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart disease or heart disease treatment that makes you prone to low blood pressure or have a family history of irregular heart beat (including QT prolongation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a history of seizures (fits) or epilepsy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a history of blood clots, or if someone else in your family has a history of blood clots, as medicines for schizophrenia have been associated with formation of blood clots</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of the hormone prolactin in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diabetes or are prone to diabetes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased kidney function</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased liver function</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an increase in your weight</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood pressure dropping upon your standing up which may cause fainting.</p><p>&nbsp;</p><p>If you have any of these conditions, please talk to your doctor as he/she may want to adjust your dose, monitor you more closely or stop treatment with Latuda.</p><p>&nbsp;</p><p><strong>Children and adolescents </strong></p><p>This medicine is not recommended for children and adolescents under 18&nbsp;years due to the lack of data in these patients.</p><p>&nbsp;</p><p><strong>Other medicines and </strong><strong>Latuda</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is especially important if you are taking:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any medicines that also work in the brain, as their effects could be additive in a negative way with the effects of Latuda on your brain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that lower blood pressure, as this medicine can also lower blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for Parkinson&rsquo;s disease and restless legs syndrome (e.g. levodopa) as this medicine can reduce their effects</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines containing ergot alkaloid derivatives (used for treating migraines), and other medicines including terfenadine and astemizole (used for treating hay fever and other allergic conditions), cisapride (used for treating digestive problems), pimozide (used to treating psychiatric illnesses), quinidine (used for treating heart conditions), bepridil (used for treating chest pain).</p><p>&nbsp;</p><p>Tell your doctor if you take any of these medicines since your doctor may have to change the dose of that medicine during treatment with Latuda.</p><p>&nbsp;</p><p>The following medicines may increase the level of lurasidone in your blood:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diltiazem (to treat high blood pressure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; erythromycin (to treat infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fluconazole (to treat fungal infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; verapamil (to treat high blood pressure or chest pain).</p><p>&nbsp;</p><p>The following medicines may decrease the level of lurasidone in your blood:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; amprenavir, efavirenz, etravirine (to treat HIV infection)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aprepitant (to treat nausea and vomiting)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; armodafinil, modafinil (to treat sleepiness)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bosentan (to treat high blood pressure or ulcers of the fingers)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nafcillin (to treat infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prednisone (to treat inflammatory disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rufinamide (to treat seizures).</p><p>&nbsp;</p><p>Tell your doctor if you take any of these medicines since your doctor may change your dose of Latuda.</p><p>&nbsp;</p><p><strong>Latuda </strong><strong>with food, drink and alcohol</strong></p><p>Alcohol should be avoided when taking this medicine. This is because alcohol will have an additive negative effect.</p><p>Do not drink grapefruit juice while you are taking this medicine. Grapefruit can affect the way this medicine works.</p><p>&nbsp;</p><p><strong>Pregnancy and breast‑feeding </strong></p><p>If you are pregnant or breast‑feeding, think you may be pregnant or planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>&nbsp;</p><p>You should not take this medicine during pregnancy unless this has been agreed with your doctor.</p><p>&nbsp;</p><p>If your doctor decides that the potential benefit of treatment during pregnancy justifies the potential risk to your unborn baby, your doctor will monitor your baby closely after birth. This is because the following symptoms may occur in newborn babies of mothers that have used lurasidone in the last trimester (last three months) of their pregnancy:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.</p><p>&nbsp;</p><p>If your baby develops any of these symptoms you should contact your doctor.</p><p>&nbsp;</p><p>It is not known if lurasidone passes into breast milk. Talk to your doctor if you are breast‑feeding, or if you plan to breast‑feed.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>Sleepiness, dizziness and vision problems may occur during treatment with this medicine (see section 4, Possible side effects). Do not drive or use any tools or machines until you know that this medicine does not affect you in a negative way.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>The recommended starting dose is 37&nbsp;mg once a day.</p><p>The dose may be increased or decreased by your doctor within the dose range of 18.5&nbsp;mg to 148&nbsp;mg once a day. The maximum dose should not exceed 148&nbsp;mg once a day.</p><p>&nbsp;</p><p>&nbsp;</p><p>Your dose will be decided by your doctor and may depend on:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; how well you respond to a dose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking some other medicines (see section 2, Other medicines and Latuda)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have kidney or liver problems.</p><p>&nbsp;</p><p>Swallow your tablet(s) whole with water, in order to mask the bitter taste. You should take your dose regularly every day at the same time of the day, so that it is easier to remember it. You must take this medicine with food or just after eating, as this helps the body to take up the medicine and allows it to work better.</p><p>&nbsp;</p><p><strong>If you take more </strong><strong>Latuda </strong><strong>than you should </strong></p><p>If you take more of this medicine than you should, contact your doctor immediately. You may experience sleepiness, tiredness, abnormal body movements, problems with standing and walking, dizziness from low blood pressure, and abnormal heart beats.</p><p>&nbsp;</p><p><strong>If you forget to take </strong><strong>Latuda</strong></p><p>Do not take a double dose to make up for a forgotten dose. If you miss one dose, take your next dose on the day after the missed dose. If you miss two or more doses, contact your doctor.</p><p>&nbsp;</p><p><strong>If you stop taking </strong><strong>Latuda</strong></p><p>If you stop taking this medicine you will lose the effects of the medicine. You should not stop this medicine unless told to do so by your doctor as your symptoms may return.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>If you notice any of the following symptoms <strong>seek medical attention immediately</strong>:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a severe allergic reaction seen as fever, swollen mouth, face, lip or tongue, shortness of breath, itching, skin rash and sometimes a drop in blood pressure. These reactions are seen rarely (may affect up to 1 in 1,000&nbsp;people).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A serious blistering rash affecting the skin, mouth, eyes and genitals (Stevens-Johnson syndrome)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever, sweating, muscle stiffness, and reduced consciousness. These could be symptoms of a condition known as neuroleptic malignant syndrome. These reactions are seen rarely (may affect up to 1 in 1,000&nbsp;people).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood clots in the veins especially in the legs (symptoms include swelling, pain and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing. If you notice any of these symptoms seek medical advice immediately.</p><p>&nbsp;</p><p>The following side effects may also happen:</p><p>&nbsp;</p><p><strong>Very common (may affect more than 1 in 10&nbsp;people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling of restlessness and inability to sit still</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleepiness.</p><p>&nbsp;</p><p><strong>Common (may affect up to 1 in 10&nbsp;people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Parkinsonism: This is a medical term that describes many symptoms which include increase in saliva secretion or watery mouth, drooling, jerks when bending the limbs, slow, reduced or impaired body movements, no expression in the face, muscle tightness, stiff neck, muscle stiffness, small, shuffling, hurried steps and lack of normal arm movements when walking, persistent blinking in response to tapping of the forehead (an abnormal reflex)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; speech problems, unusual muscle movements; a collection of symptoms known as extrapyramidal symptoms (EPS) which typically will involve unusual purposeless involuntary muscle movements.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasms and stiffness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea (feeling sick), vomiting (being sick)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth or excess saliva</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty sleeping, tiredness, agitation and anxiety</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight gain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in creatine phosphokinase (an enzyme in muscles) seen in blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in creatinine (a marker of kidney function) seen in blood tests.</p><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100&nbsp;people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slurred speech</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nightmares</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle aches</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pains</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems walking</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rigid posture</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood prolactin, increased blood glucose (blood sugar), increase in some liver enzymes, seen in blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood pressure dropping upon standing up which may cause fainting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; common cold</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hot flush</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain when passing urine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; uncontrollable movements of mouth, tongue and limbs (tardive dyskinesia).</p><p>&nbsp;</p><p><strong>Rare (may affect up to 1 in 1,000&nbsp;people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rhabdomyolysis which is the breakdown of muscle fibres that leads to the release of muscle fibre contents (myoglobin) into the bloodstream, seen as muscle pain, being sick, being confused, an abnormal heart rate and rhythm, and possibly dark urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in eosinophils (a type of white blood cell).</p><p>&nbsp;</p><p><strong>Not known (frequency cannot be estimated from the available data):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced levels of white blood cells (which fight infection) and red blood cells (which carry oxygen around the body)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; deliberate injury to oneself</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden feelings of anxiety</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleep disorder</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spinning sensation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizure (fits)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal nerve impulses in the heart</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slow heart rate</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty swallowing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the tongue or throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irritation to lining of stomach</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash, which may be itchy and include swelling, blistering or red patches on the skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; newborn babies may show the following: agitation, increase or decreases in muscle tone, tremor, sleepiness, breathing or feeding problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal breast enlargement, breast pain, milk secretion from breasts</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems with erections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; painful or absence of menstrual periods</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden death associated with heart disease.</p><p>&nbsp;</p><p>In elderly people with dementia, a small increase in the number of deaths has been reported for patients taking medicines for schizophrenia compared with those not receiving these medicines.</p><p>&nbsp;</p><p><strong>Reporting of side effects </strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.</p><p>Do not store above 30&deg;C.</p><p>Store in the original package in order to protect from light.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is lurasidone.</p><p>Each 18.5&nbsp;mg tablet contains lurasidone hydrochloride equivalent to 18.6&nbsp;mg lurasidone.</p><p>Each 37&nbsp;mg tablet contains lurasidone hydrochloride equivalent to 37.2&nbsp;mg lurasidone.</p><p>Each 74&nbsp;mg tablet contains lurasidone hydrochloride equivalent to 74.5&nbsp;mg lurasidone.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are mannitol, pregelatinised starch, croscarmellose sodium, hypromellose, magnesium stearate (E470b), titanium dioxide (E171), macrogol, yellow iron oxide (E172) (present in 74&nbsp;mg tablets), indigotine (E132) (present in 74&nbsp;mg tablets) and carnauba wax (E903).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                •	Latuda 18.5 mg film coated tablets are white to off white, film coated round tablets debossed with “LA”
•	Latuda 37 mg film coated tablets are white to off white, film coated round tablets debossed with “LB”
•	Latuda 74 mg film coated tablets are pale green, film coated oval tablets debossed with “LD”.

Latuda film coated tablets are available in pack sizes containing 28 film coated tablet in aluminium/aluminium perforated unit dose blisters (2 blister strips, each containing 14 film coated tablets).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Sunovion Pharmaceuticals Europe Ltd.</p><p>First Floor</p><p>Southside</p><p>97-105 Victoria Street</p><p>London</p><p>SW1E 6QT</p><p>United Kingdom</p><p>&nbsp;</p><p><strong>Bulk Manufacturer</strong></p><p>Bushu Pharmaceuticals Ltd.</p><p>1 Takeno, Kawagoe, Saitama, 350-0801</p><p>Japan</p><p>&nbsp;</p><p><strong>Batch Releaser</strong></p><p>AndersonBrecon (UK) Ltd.</p><p>Units 2-7</p><p>Wye Valley Business Park</p><p>Brecon Road</p><p>Hay-on-Wye</p><p>Hereford</p><p>HR3 5PG</p><p>United Kingdom</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                03/2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي دواء لاتودا على المادة الفعَّالة لوراسيدون وينتمي إلى مجموعة أدوية تُسمى مضادات الذهان. ويُستخدَم هذا الدواء لعلاج أعراض الفُصَام لدى البالغين ممن تبلغ أعمارهم 18 سنة فأكثر. ويعمل لوراسيدون من خلال إحصار المستقبلات في المخ والتي ترتبط بها مادتا دُوبامِين وسيرُوتُونين. ومعروف أن دُوبامِين وسيرُوتُونين نواقل عصبية (أي مواد تتيح للخلايا العصبية التَّواصل مع بعضها البعض) لها دور في حدوث أعراض الفُصَام. ومن خلال إحصار هذين المستقبلين، فإنَّ لوراسيدون يُساعد على إعادة النَّشاط الطبيعي إلى المخ، مما يقلل من أعراض الفُصَام.</p><p>&nbsp;</p><p dir="RTL">الفُصَام عبارة عن اضطراب تصحبه أعراض مثل: رؤية أشياء أو سماع صوت أشياء أو الشعور بأشياء غير موجودة، وتكون معتقدات خاطئة، وارتياب غير معتاد، والانطواء، والكلام غير المترابط وتبلد المشاعر والسلوك. وقد يشعر أيضًا الأشخاص الذين يعانون من هذا الاضطراب بالاكتئاب أو القلق أو الذنب أو التَّوتر. ويُستخدم هذا الدَّواء لتحسين أعراض الفُصَام.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p dir="RTL"><strong>لا تتناول دواء لاتودا</strong><strong> في الحالات الآتية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية تجاه لوراسيدون أو أي مكونات أخرى بهذا الدَّواء (المدرجة في قسم 6)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية ربما تُؤثر على مستوى لوراسيدون في الدَّم مثل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج العدوى الفطرية مثل: إتراكونازول أو كيتوكونازول (إلا إذا كان في صورة شامبو) أو پوساکونازول أو فوريكونازول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج العدوى مثل: المضاد الحيوي كلاريثروميسين أو تيليثروميسين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج عدوى فيروس نقص المناعة البشرية &quot;HIV&quot; مثل: كوبيسيستات وإندينافير ونيلفينافير وريتونافير وساكوينافير</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بوسيبريفير وتيلايريفير (دواءان يستخدمان لعلاج التهاب الكبد المزمن)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نيفازودون (دواء لعلاج الاكتئاب).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رِيفامبيسِين (دواء يُستخدم لعلاج السل)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كَرْبامازِيبين وفينوباربيتال وفينيتوين (أدوية تُستخدم لعلاج النوبات التشنجية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جونز <em>(هايبريكوم برفوراتام)</em> (دواء عشبي يُستخدم لعلاج الاكتئاب).</p><p>&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات </strong></p><p dir="RTL">قد يستغرق الأمر عدة أيام أو حتى أسابيع حتى يظهر التَّأثير الكامل لهذا الدَّواء. ويُرجى الاتصال بالطبيب إذا كانت لديك أي أسئلة تتعلق بهذا الدَّواء.</p><p>&nbsp;</p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل تناول هذا الدَّواء أو أثناء العلاج، خاصةً في الحالات الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض الشلل الرعَّاش (مرض باركنسون) أو الخرف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان قد تم تشخيصك في أي وقت بأنك تعاني من حالة والتي تشمل أعراضها تصلب العضلات وارتفاع درجة الحرارة (تعرف أيضًا باسم المُتَلَازِمَة الخَبيثَة للدَّواءِ المُضادِّ للذُّهان) أو إذا عانيت في أي وقت من التَّصلب أو الارتعاش العضلي أو مشاكل في الحركة (أعراض خلل النظام العصبي الحركي) أو حركات غير طبيعية في اللسان أو الوجه (خَلل الحَرَكَةِ المُتَأخِّر). ويجب أن تدرك أن هذه الحالات ربما تنجم عن هذا الدَّواء<strong><em> </em></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض بالقلب أو تتناول علاجًا لمرض بالقلب من شأنه أن يعرضك لحدوث انخفاض في ضغط الدَّم أو كان لديك تاريخ عائلي من الإصابة بعدم انتظام ضربات القلب (بما في ذلك إطالة فترة QT).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ سابق من الإصابة بالنوبات التشنجية أو الصرع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أنت أو شخص ما في عائلتك لديه تاريخ سابق لحدوث جلطات الدَّم؛ حيث إنه قد تم الربط بين أدوية الفصام وتكوُّن جلطات الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان هرمون البرولاكتين موجودًا في الدَّم لديك بمستويات زائدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمرض السكري أو عرضة للإصابة به.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك ضعف وظائف الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك ضعف وظائف الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان وزنك زائدًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض ضغط الدَّم عند النهوض مما قد يُسبب إغماء.</p><p>&nbsp;</p><p dir="RTL">إذا كنت تعاني من أي حالات مرضية أخرى، فيُرجى التحدُّث إلى طبيبك؛ لأنه ربما يحتاج إلى ضبط جرعتك أو وضعك تحت الملاحظة عن كثب أو إيقاف العلاج بدواء لاتودا.</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون </strong></p><p dir="RTL">لا ينصح باستخدام هذا الدَّواء للأطفال والمراهقين أقل من 18 عامًا نتيجة نقص البيانات الخاصَّة بتأثيره على هؤلاء المرضى.</p><p>&nbsp;</p><p dir="RTL"><strong>أدوية أخرى مع دواء لاتودا</strong></p><p dir="RTL">يُرجى إبلاغ الطبيب أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى. هذا هام خاصةً إذا كنت تتناول:</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي أدوية تُؤثر أيضًا على المخ؛ لأن تأثيرها ربما يكون مضافًا بشكل سلبي مع تأثيرات دواء لاتودا على المخ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لخفض ضغط الدَّم؛ لأن هذا الدَّواء يمكنه أيضًا خفض ضغط الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج مرض الشلل الرعَّاش (مرض باركنسون) ومتلازمة تململ الساقين (مثل: ليفودوبا)؛ لأن هذا الدَّواء يمكنه تقليل تأثيرات تلك الأدوية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تحتوي على مشتقات قلواني الإرغوت (تُستخدم لعلاج الصداع النصفي)، وأدوية أخرى من بينها تيرفينادين وأستيمزول (تُستخدم لعلاج حُمَّى القش وحالات حساسية أخرى)، سيسابريد (يُستخدم لعلاج مشاكل الهضم)، بيموزيد (يُستخدم لعلاج الأمراض النفسية)، كينيدين (يُستخدم لعلاج الحالات المرضية القلبية)، بيبريديل (يُستخدم لعلاج ألم الصدر).</p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أيًّا من هذه الأدوية التَّالية حيث ربما يحتاج طبيبك لأن يغير جرعة الدَّواء أثناء العلاج بدواء لاتودا.</p><p>&nbsp;</p><p dir="RTL">من شأن الأدوية التَّالية زيادة مستوى لوراسيدون في الدَّم لديك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديلتِيازِيم (لعلاج ارتفاع ضغط الدَّم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إريثروميسين (دواء يُستخدم لعلاج العدوى).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فلوكونازول (دواء يُستخدم لعلاج العدوى الفطرية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيراباميل (دواء يُستخدم لعلاج ارتفاع ضغط الدَّم أو ألم الصدر).</p><p>&nbsp;</p><p dir="RTL">من شأن الأدوية التَّالية تقليل مستوى لوراسيدون في الدَّم لديك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمبرينافير، إيفافيرينز، إترافيرين (عقاقير تُستخدم لعلاج عدوى فيروس نقص المناعة البشرية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أبريبيتانت (دواء يُستخدم لعلاج الغثيان والقيء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أرمودافينيل، مودافينيل (دواءان يُستخدمان لعلاج النعاس).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بوسينتان (دواء يُستخدم لعلاج ارتفاع ضغط الدَّم أو قرح الأصابع).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نافْسِيلِّين (دواء يُستخدم لعلاج العدوى).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بريدنيزون (دواء يُستخدم لعلاج المرض الالتهابي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; روفينامايد (دواء يُستخدم لعلاج النوبات التشنجية).</p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أيًّا من هذه الأدوية التَّالية؛ حيث ربما يحتاج طبيبك لأن يغير جرعة دواء لاتودا.</p><p>&nbsp;</p><p dir="RTL"><strong>تناوُل دواء لاتودا </strong><strong>مع الأطعمة والمشروبات والكحوليات</strong></p><p dir="RTL">يجب عدم تعاطي الكحوليات أثناء تناول هذا الدَّواء. وهذا لأن للكحوليات تأثيرًا سلبيًّا إضافيًّا.</p><p dir="RTL">يجب عدم شرب عصير الجريب فروت أثناء تناول هذا الدَّواء. حيث يمكن أن يُؤثر الجريب فروت على طريقة عمل هذا الدَّواء.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية </strong></p><p dir="RTL">إذا كنتِ حاملًا أو مرضعًا، أو تعتقدين أنكِ حامل أو تخططين لذلك، فاستشيري طبيبك قبل تناوُل هذا الدَّواء.</p><p>&nbsp;</p><p dir="RTL">يجب ألا تتناولي هذا الدَّواء أثناء الحمل، ما لم يخبرك طبيبك بخلاف ذلك.</p><p>&nbsp;</p><p dir="RTL">إذا رأى الطبيب أنَّ الفائدة المرجوة للعلاج أثناء الحمل تبرر المخاطر المحتمل تعرض الجنين لها، فسيضع الطبيب الطفل بعد ولادته تحت الملاحظة عن كثب. وذلك لأنه قد تحدث الأعراض التَّالية في الأطفال حديثي الولادة، للأمهات اللاتي كن قد استخدمن لوراسيدون في الثلث الأخير من الحمل (الثلاثة أشهر الأخيرة من الحمل):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتعاش وتصلب و/ أو ضعف العضلات ونعاس وهِياج ومشاكل بالتَّنفس وصعوبة في التَّغذية.</p><p>&nbsp;</p><p dir="RTL">إذا تطورت لدى طفلكِ أيٌّ من هذه الأعراض فقد تحتاجين إلى الاتصال بطبيبكِ.</p><p>&nbsp;</p><p dir="RTL">من غير المعروف ما إذا كان لوراسيدون يمر في لبن الثدي. أخبري طبيبكِ إذا كنتِ تُرضعين طبيعيًّا، أو تعتزمين الرضاعة الطبيعية.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">قد يحدث نعاس ودوخة ومشاكل في الرؤية أثناء العلاج بهذا الدَّواء (انظر القسم 4، الآثار الجانبية المحتملة). ولا ينبغي للشَّخص أن يقود أو يستخدم أي أدوات أو آلات حتى يتأكد أن الدَّواء لا يُؤثر عليه بطريقة سلبية.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا هذا الدَّواء بالضبط كما أخبرك الطبيب أو الصيدلي الخاص بك. يُرجى مراجعة طبيبك أو الصيدلي إذا لم تكن متأكدًا من كيفية التَّناول.</p><p>&nbsp;</p><p dir="RTL">الجرعة الموصى بها هي 37 مجم مرة واحدة يوميًّا.</p><p dir="RTL">قد يزيد الطبيب الجرعة أو يقللها ضمن نطاق جرعة يتراوح بين 18.5 مجم و148&nbsp;مجم مرة واحدة في اليوم. ويجب عدم تجاوز الجرعة القصوى البالغة 148 مجم مرة واحدة في اليوم.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">سيقوم طبيبك بتحديد الجرعة الخاصة بك وسيتوقف ذلك على:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مدى استجابتك للجرعة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ما إذا كنتَ تتناول بعض الأدوية الأخرى (يُرجى الرجوع إلى القسم رقم 2، تناول لاتودا مع الأدوية الأخرى)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أمراض بالكبد أو الكلى.</p><p>&nbsp;</p><p dir="RTL">ابتلع القرص كاملًا (الأقراص كاملة) بالماء، كي لا تشعر بالمرارة. ويجب أن تتناوُل جرعتك بشكل منتظم كل يوم في نفس الوقت، كي يسهل عليك تذكرها. كما يجب أن تتناول هذا الدَّواء مع الطعام أو بعد الأكل مباشرة؛ لأن ذلك يُساعد الجسم على استيعاب الدَّواء ويُساهم في عمله بشكل أفضل.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا تناولت كمية أكثر مما يجب من دواء لاتودا</strong></p><p dir="RTL">إذا تناولت كمية من هذا الدَّواء أكثر مما يجب، اتصل بطبيبك على الفور. قد تشعر بنعاس وإجهاد، وحركات جسم غير طبيعية، ومشاكل عند النهوض والمشي، وحدوث دوخة نتيجة انخفاض ضغط الدَّم، واضطراب ضربات القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أغفلت تناوُل دواء لاتودا</strong></p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض جرعة أغفلتها. إذا أغفلت تناول إحدى الجرعات، فتناول جرعتك التَّالية في ذاك اليوم بعد الجرعة التي أغفلتها. أما إذا أغفلت تناول جرعتين أو أكثر، فاتصل بطبيبك.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول دواء لاتودا</strong></p><p dir="RTL">إذا توقفت عن تناول هذا الدَّواء فستزول آثاره. لذا لا يجب أن تتوقف عن تناول هذا الدَّواء ما لم يخبرك طبيبك بذلك؛ لأن الأعراض ربما تعود ثانية.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر الطبيب أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p>&nbsp;</p><p dir="RTL">إذا لاحظت أيًّا من الأعراض التَّالية فينبغي عليك <strong>طلب العناية الطبية فورًا</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية شديد يظهر على هيئة حمى، تورم الفم أو الوجه أو الشفاه أو اللسان، ضيق في التَّنفس، حكة، طفح جلدي وفي بعض الأحيان انخفاض في ضغط الدَّم. تكون هذه التفاعلات نادرة (قد تُؤثر في ما يصل إلى شخص واحد من كل 1000 شخص).</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي خطير يظهر على هيئة نفطات ويُؤثر على الجلد والفم والعينين والأعضاء التَّناسلية (متلازمة ستيفنز جونسون)</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى، تعرُّق، تصلب العضلات وضعف الوعي. فقد تكون هذه أعراضًا لحالة تعرف باسم المُتَلَازِمَة الخَبيثَة للدَّواءِ المُضادِّ للذُّهان. تكون هذه التفاعلات نادرة (قد تُؤثر في ما يصل إلى شخص واحد من كل 1000 شخص).</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجلطات دموية بالأوردة خاصةً بالساقين (تتضمن الأعراض: تورمًا، ألمًا، واحمرارًا في السَّاق)، والتي قد تنتقل عبر الأوعية الدَّموية إلى الرئتين وتتسبب في ألم في الصدر وصعوبة في التَّنفس. إذا لاحظت أيًّا من هذه الأعراض فأسعى في طلب المشورة الطبية على الفور.</p><p>&nbsp;</p><p dir="RTL">قد تحدث أيضًا الآثار الجانبية التَّالية:</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة جدًّا (قد تؤثر في أكثر من </strong><strong>1</strong><strong> من كل </strong><strong>10</strong><strong>&nbsp;أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالتململ وعدم القدرة على الجلوس بشكل ثابت</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النعاس.</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل </strong><strong>10</strong><strong>&nbsp;أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البَاَرْكِنْسُونِيَّة: هذا عبارة عن مصطلح طبي يصف أعراضًا كثيرة من بينها زيادة في إفراز اللعاب أو تكون اللعاب في الفم، سيلان اللعاب، الاهتزاز عند ثني الأطراف، بطء حركات الجسم أو قلتها أو ضعفها، عدم ظهور تعبيرات على الوجه، الشد العضلي، تصلب الرقبة، تصلب العضلات، المشي بخطوات قصيرة أو متثاقلة أو متسارعة وعدم تحريك الذراع بشكل طبيعي أثناء المشي، غلق العينين وفتحهما باستمرار عند النقر فوق الجبهة (فعل انعكاسي غير طبيعي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في التَّحدث، حركات عضلية غير معتادة، مجموعة من الأعراض تعرف باسم أعراض خلل النظام العصبي الحركي(EPS) &nbsp;وتتضمن في العادة حركات عضلية لا إرادية وغير معتادة وبلا هدف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلص العضلات وتصلبها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان (شعور بالإعياء)، قيء (إعياء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر الهضم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جُفافُ الفَم أو زيادة إفراز اللعاب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالبطن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم، إجهاد، هِياج وقلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في فسْفُوكيناز الكْرياتين (إنزيم في العضلات) تمت ملاحظتها في اختبارات الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في الكِرْياتينين (دلالة لوظيفة الكُلى) تمت ملاحظتها في اختبارات الدَّم.</p><p>&nbsp;</p><p dir="RTL"><strong>غير شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل </strong><strong>100</strong><strong> شخص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التلعثم في الكلام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كوابيس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام بالعضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المفاصل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في المشي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلب وضعية الجسم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في برولاكتين الدَّم، زيادة في جلوكوز الدَّم (سكر الدَّم)، زيادة في بعض إنزيمات الكبد، تمت ملاحظتها في اختبارات الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدَّم عند النهوض مما قد يُسبب إغماء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات قلب سريعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزلات البرد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبات ساخنة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الشهية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم عند التَّبول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحرك الفم واللسان والأطراف بشكل لا يمكن التَّحكم فيه (خَللُ الحَرَكَةِ المُتَأخِّر).</p><p>&nbsp;</p><p dir="RTL"><strong>نادرة (في ما يصل إلى شخص واحد من بين كل </strong><strong>1000</strong><strong> شخص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انحلال الربيدات وتعني انحلال ألياف العضلات مما يُؤدي إلى انطلاق محتويات ألياف العضلات (الميوجلوبين) في مجرى الدَّم، ولُوحظ ذلك على هيئة ألم عضلي، إعياء، ارتباك، اضطراب نظم وضربات القلب، وربما بول داكن اللون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة اليوزينات (نوع من خلايا الدَّم البيضاء).</p><p>&nbsp;</p><p dir="RTL"><strong>غير معروفة (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص مستويات خلايا الدَّم البيضاء (المعنية بمكافحة العدوى) وخلايا الدَّم الحمراء (المعنية بنقل الأكسجين حول الجسم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيذاء النفس عمدًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور مفاجئ بالقلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب النَّوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوران.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة تشنجية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالصدر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبضات عصبية غير طبيعية في القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض معدل ضربات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إِسْهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;صعوبة البلع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في اللسان أو الحلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيُّج بطانة المعدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، ربما يكون مثيرًا للحكة ويتضمن حدوث تورم أو ظهور نفطات أو بقع حمراء على الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفشل الكلوي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ربما يعاني الأطفال حديثو الولادة مما يلي: هياج، زيادة التوتر العضلي أو انخفاضه، ارتعاش، نعاس، مشاكل في التنفس أو التغذية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الثدي بشكل غير طبيعي، ألم بالثدي، إفراز حليب من الثديين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات في الانتصاب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انعدام دورات الحيض أو مجيئها مصحوبة بالألم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وفاة مفاجئة مقترنة بمرض بالقلب.</p><p>&nbsp;</p><p dir="RTL">في المرضى من كبار السن الذين يعانون من الخرف, تم الإبلاغ عن زيادة طفيفة في عدد الوفيات للمرضى الذين يتناولون مضادات الذهان مقارنة بأولئك الذين لا يتلقون هذه الأدوية.</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية </strong></p><p dir="RTL">إذا ظهرت لديك أية آثار جانبية، فتحدَّث إلى الطبيب أو الصيدلي الخاص بك بما في ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة. من خلال إبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدَّواء.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة والشريط بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تخزن الدواء في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">يخزن داخل العبوة الأصلية للحماية من الضوء.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. سوف تُساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما الذي يحتوي عليه دواء لاتودا؟</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; المادة الفعالة هي لوراسيدون.</p><p dir="RTL">يحتوي كل قرص 18.5 مجم على هيدروكلوريد لوراسيدون بما يُعادل 18.6 مجم لوراسيدون.</p><p dir="RTL">يحتوي كل قرص 37 مجم على هيدروكلوريد لوراسيدون بما يُعادل 37.2 مجم لوراسيدون.</p><p dir="RTL">يحتوي كل قرص 74 مجم على هيدروكلوريد لوراسيدون بما يُعادل 74.5 مجم لوراسيدون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي مانيتول، نشا سابق التجلتن، كروسكارميلوز الصوديوم، هيبروميلوز، ستيرات الماغنسيوم (E470b)، ثاني أكسيد التيتانيوم (E171)، ماكروجول، أكسيد الحديد الأصفر (E172) (يوجد في الأقراص 74 مجم)، إنديجوتين (E132) (يوجد في الأقراص 74 مجم) وشمع كرنوبا (E903).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل دواء لاتودا؟ وما هي محتويات العبوة؟</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء لاتودا أقراص مغلفة 18.5 مجم عبارة عن أقراص مغلَّفة دائرية الشَّكل، ذات لون أبيض إلى عاجي، محفور عليها الحرفان &quot;LA&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء لاتودا أقراص مغلفة 37 مجم عبارة عن أقراص مغلَّفة دائرية الشَّكل، ذات لون أبيض إلى عاجي، محفور عليها الحرفان &quot;LB&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء لاتودا أقراص مغلفة 74 مجم عبارة عن أقراص مغلَّفة بيضاوية الشكل، ذات لون أخضر شاحب، محفور عليها الحرفان &quot;LD&quot;.</p><p>&nbsp;</p><p dir="RTL">دواء لاتودا أقراص مغلفة متوفر في عبوة تحتوي على28 &nbsp;قرصًا مغلفًا في شرائط ألمونيوم/ألمونيوم مثقوبة (شريطين ، يحتوى كل شريط على 14 قرصًا مغلفًا).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p dir="RTL"><strong>مالك </strong><strong>رخصة</strong><strong> ا</strong><strong>لتَّسويق</strong></p><p>Sunovion Pharmaceuticals Europe Ltd.</p><p>First Floor</p><p>Southside</p><p>97-105 Victoria Street</p><p>London</p><p>SW1E 6QT</p><p>United Kingdom</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>جهة التَّصنيع</strong></p><p>Bushu Pharmaceuticals Ltd.</p><p>1 Takeno, Kawagoe, Saitama, 350-0801</p><p>Japan</p><p>&nbsp;</p><p dir="RTL"><strong>Batch Releaser</strong></p><p>AndersonBrecon (UK) Ltd.</p><p>Units 2-7</p><p>Wye Valley Business Park</p><p>Brecon Road</p><p>Hay-on-Wye</p><p>Hereford</p><p>HR3 5PG</p><p>United Kingdom</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            03/2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Latuda 74 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains lurasidone hydrochloride equivalent to 74.5 mg lurasidone. For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).

Latuda 74 mg film-coated tablets: pale green, film-coated oval tablets of 12 mm x 7 mm debossed with ‘LD’



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.1&nbsp;&nbsp;&nbsp; Therapeutic indications</strong></p><p>&nbsp;</p><p>Latuda is indicated for the treatment of schizophrenia in adults aged 18 years and over.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.2&nbsp;&nbsp;&nbsp; Posology and method of administration</strong></p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>The recommended starting dose of lurasidone is 37 mg once daily. No initial dose titration is required. It is effective in a dose range of 37 to 148 mg once daily. Dose increase should be based on physician judgement and observed clinical response. The maximum daily dose should not exceed 148 mg.</p><p>&nbsp;</p><p>Patients on doses higher than 111 mg once daily who discontinue their treatment for longer than</p><p>3 days should be restarted on 111 mg once daily and up-titrated to their optimal dose. For all other doses patients can be restarted on their previous dose without need for up-titration.</p><p>&nbsp;</p><p><em>Elderly people</em></p><p>Dosing recommendations for elderly patients with normal renal function (CrCl &ge; 80 ml/min) are the same as for adults with normal renal function. However, because elderly patients may have diminished renal function, dose adjustments may be required according to their renal function status (see &ldquo;Renal impairment&rdquo; below).</p><p>&nbsp;</p><p>Limited data are available in elderly people treated with higher doses of lurasidone. No data are available in elderly people treated with Latuda 148 mg. Caution should be exercised when treating patients &ge;65 years of age with higher doses of Latuda.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment of lurasidone is required in patients with mild renal impairment.</p><p>In patients with moderate (Creatinine Clearance (CrCl) &ge; 30 and &lt; 50 ml/min), severe renal impairment (CrCL &gt;15 and &lt; 30 ml/min) and End Stage Renal Disease (ESRD) patients</p><p>&nbsp;</p><p>(CrCl &lt; 15 ml/min), the recommended starting dose is 18.5 mg and the maximum dose should not exceed 74 mg once daily. Latuda should not be used in patients with ESRD unless the potential benefits outweigh the potential risks. If used in ESRD, clinical monitoring is advised.</p><p>&nbsp;</p><p><em>H</em><em>epatic impairment</em></p><p>No dose adjustment of lurasidone is required in patients with mild hepatic impairment.</p><p>Dose adjustment is recommended in moderate (Child-Pugh Class B) and severe hepatic impairment</p><p>(Child-Pugh Class C) patients. The recommended starting dose is 18.5 mg. The maximum daily dose in moderate hepatic impairment patients should not exceed 74 mg and in severe hepatic impairment</p><p>patients should not exceed 37 mg once daily.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of lurasidone in children aged less than 18 years have not been established. Current available data are described in section 5.2, but no recommendation on a posology can be</p><p>made.</p><p>&nbsp;</p><p><em>D</em><em>ose adjustment due to interactions</em></p><p>A starting dose of 18.5 mg is recommended and the maximum dose of lurasidone should not exceed</p><p>74 mg once daily in combination with moderate CYP3A4 inhibitors. Dose adjustment of lurasidone may be necessary in combination with mild and moderate CYP3A4 inducers (see section 4.5). For strong CYP3A4 inhibitors and inducers see section 4.3.</p><p>&nbsp;</p><p><em>Switching between antipsychotic medicinal products</em></p><p>Due to different pharmacodynamic and pharmacokinetic profiles among antipsychotic medicinal products, supervision by a clinician is needed when switching to another antipsychotic product is considered medically appropriate.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Latuda film-coated tablets are for oral use, to be taken once daily together with a meal.</p><p>If taken without food, it is anticipated that lurasidone exposure will be significantly lower as compared to when taken with food (see section 5.2).</p><p>&nbsp;</p><p>Latuda tablets should be swallowed whole, in order to mask the bitter taste. Latuda tablets should be taken at the same time every day to aid compliance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4.3	Contraindications

-	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
-	Concomitant administration of strong CYP3A4 inhibitors (e.g. boceprevir, clarithromycin, cobicistat, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole,
ritonavir, saquinavir, telaprevir, telithromycin, voriconazole) and strong CYP3A4 inducers (e.g.
carbamazepine, phenobarbital, phenytoin, rifampicin, St John’s wort (Hypericum perforatum) (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.4&nbsp;&nbsp;&nbsp; Special warnings and precautions for use</strong></p><p>&nbsp;</p><p>During antipsychotic treatment, improvement in the patient&#39;s clinical condition may take a few days to some weeks. Patients should be closely monitored during this period.</p><p>&nbsp;</p><p><u>Suicidality</u></p><p>The occurrence of suicidal behaviour is inherent in psychotic illnesses and in some cases has been reported early after initiation or switch of antipsychotic therapy. Close supervision of high-risk</p><p>patients should accompany antipsychotic therapy.</p><p>&nbsp;</p><p><u>Parkinson&rsquo;s disease</u></p><p>If prescribed to patients with Parkinson&rsquo;s disease, antipsychotic medicinal products may exacerbate the underlying parkinsonism symptoms. Physicians should therefore weigh the risks versus the benefits when prescribing Latuda to patients with Parkinson&rsquo;s disease.</p><p>&nbsp;</p><p><u>Extrapyramidal symptoms (EPS)</u></p><p>Medicinal products with dopamine receptor antagonistic properties have been associated with extrapyramidal adverse reactions including rigidity, tremors, mask-like face, dystonias, drooling of</p><p>saliva, drooped posture and abnormal gait. In placebo controlled clinical studies in adult patients with schizophrenia there was an increased occurrence of EPS following treatment with lurasidone</p><p>compared to placebo.</p><p>&nbsp;</p><p><u>T</u><u>a</u><u>r</u><u>dive dyskinesia</u></p><p>Medicinal products with dopamine receptor antagonistic properties have been associated with the induction of tardive dyskinesia characterised by rhythmical involuntary movements, predominantly of the tongue and/or face. If signs and symptoms of tardive dyskinesia appear, the discontinuation of all antipsychotics, including lurasidone, should be considered.</p><p>&nbsp;</p><p><u>C</u><u>ardiovascular disorders/QT prolongation</u></p><p>Caution should be exercised when lurasidone is prescribed in patients with known cardiovascular disease or family history of QT prolongation, hypokalaemia, and in concomitant use with other</p><p>medicinal products thought to prolong the QT interval.</p><p>&nbsp;</p><p><u>Seizures</u></p><p>Lurasidone should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold.</p><p>&nbsp;</p><p><u>N</u><u>euroleptic malignant syndrome (NMS)</u></p><p>Neuroleptic Malignant Syndrome, characterised by hyperthermia, muscle rigidity, autonomic instability, altered consciousness and elevated serum creatine phosphokinase levels, has been reported to occur with antipsychotics including lurasidone. Additional signs may include myoglobinuria (rhabdomyolysis) and acute renal failure. In this event, all antipsychotics, including lurasidone, should be discontinued.</p><p>&nbsp;</p><p><u>Elderly patients with dementia</u></p><p>Lurasidone has not been studied in elderly patients with dementia.</p><p>&nbsp;</p><p><u>O</u><u>v</u><u>erall mortality</u></p><p>In a meta-analysis of 17 controlled clinical trials, elderly patients with dementia treated with other atypical antipsychotics, including risperidone, aripiprazole, olanzapine, and quetiapine had an increased risk of mortality compared to placebo.</p><p>&nbsp;</p><p><u>C</u><u>erebrovascular accident</u></p><p>An approximately 3-fold increased risk of cerebrovascular adverse reactions has been seen in randomised placebo-controlled clinical trials in the dementia population with some atypical antipsychotics, including risperidone, aripiprazole and olanzapine. The mechanism for this increased risk is not known. An increased risk cannot be excluded for other antipsychotics or other patient populations. Lurasidone should be used with caution in elderly patients with dementia who have risk factors for stroke.</p><p>&nbsp;</p><p><u>V</u><u>enous thromboembolism</u></p><p>Cases of venous thromboembolism (VTE) have been reported with antipsychotic medicinal products. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible</p><p>risk factors for VTE should be identified before and during treatment with lurasidone and preventive measures undertaken.</p><p>&nbsp;</p><p><u>H</u><u>y</u><u>perprolactinaemia</u></p><p>Lurasidone elevates prolactin levels due to antagonism of dopamine D2 receptors.</p><p>&nbsp;</p><p><u>Weight gain</u></p><p>Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.</p><p>&nbsp;</p><p><u>H</u><u>y</u><u>perglycaemia</u></p><p>Rare cases of glucose related adverse reactions, e.g. increase in blood glucose, have been reported in clinical trials with lurasidone. Appropriate clinical monitoring is advisable in diabetic patients and in patients with risk factors for the development of diabetes mellitus.</p><p>&nbsp;</p><p><u>O</u><u>rt</u><u>hostatic hypotension/syncope</u></p><p>Lurasidone may cause orthostatic hypotension, perhaps due to its &alpha;1-adrenergic receptor antagonism. Monitoring of orthostatic vital signs should be considered in patients who are vulnerable to hypotension.</p><p>&nbsp;</p><p><u>R</u><u>enal impairment</u></p><p>Dose adjustment is recommended for patients with moderate and severely impaired renal function and in patients with ESRD. Use in patients with ESRD has not been investigated and therefore lurasidone should not be used in patients with ESRD unless the potential benefits outweigh the potential risks. If used in patients with ESRD, clinical monitoring is advised (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><u>H</u><u>epatic impairment</u></p><p>Dose adjustment is recommended for patients with moderate and severely impaired hepatic function</p><p>(Child-Pugh Class B and C) (see sections 4.2 and 5.2). Caution is recommended in patients with severely impaired hepatic function.</p><p>&nbsp;</p><p><u>I</u><u>nteraction with Grapefruit juice</u></p><p>Grapefruit juice should be avoided during treatment with lurasidone (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.5&nbsp;&nbsp;&nbsp; Interaction with other medicinal products and other forms of interaction</strong></p><p>&nbsp;</p><p><u>Pharmacodynamic interactions</u></p><p>&nbsp;</p><p>Given the primary central nervous system effects of lurasidone, lurasidone should be used with caution in combination with other centrally acting medicinal products and alcohol.</p><p>&nbsp;</p><p>Caution is advised when prescribing lurasidone with medicinal products known to prolong the QT interval, e.g. class IA antiarrhythmics (e.g. quinidine, disopyramide) and class III antiarrhythmics (e.g. amiodarone, sotalol), some antihistaminics, some other antipsychotics and some antimalarials (e.g. mefloquine).</p><p>&nbsp;</p><p><u>Pharmacokinetic interactions</u></p><p>&nbsp;</p><p>The concomitant administration of lurasidone and grapefruit juice has not been assessed. Grapefruit juice inhibits CYP 3A4 and may increase the serum concentration of lurasidone. Grapefruit juice should be avoided during treatment with lurasidone.</p><p>&nbsp;</p><p><u>Potential for other medicinal products to affect lurasidone</u></p><p>&nbsp;</p><p>Lurasidone and its active metabolite ID-14283 both contribute to the pharmacodynamic effect at the dopaminergic and serotonergic receptors. Lurasidone and its active metabolite ID-14283 are primarily metabolised by CYP3A4.</p><p>&nbsp;</p><p><em>C</em><em>Y</em><em>P3A4 inhibitors</em></p><p>Lurasidone is contraindicated with strong CYP3A4 inhibitors (e.g. boceprevir, clarithromycin, cobicistat, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole) (see section 4.3).</p><p>&nbsp;</p><p>Coadministration of lurasidone with the strong CYP3A4 inhibitor ketoconazole resulted in a 9- and</p><p>6-fold increase in exposure of lurasidone and its active metabolite ID-14283 respectively.</p><p>&nbsp;</p><p>Coadministration of lurasidone with medicinal products that moderately inhibit CYP3A4 (e.g. diltiazem, erythromycin, fluconazole verapamil) may increase exposure to lurasidone. Moderate CYP3A4 inhibitors are estimated to result in a 2-5-fold increase in exposure of CYP3A4 substrates.</p><p>&nbsp;</p><p>Coadministration of lurasidone with diltiazem (slow-release formulation), a moderate CYP3A4 inhibitor, resulted in a 2.2 and 2.4-fold increase in exposure of lurasidone and ID-14283 respectively (see section 4.2). The use of an immediate release formulation of diltiazem could result in a larger increase in lurasidone exposure.</p><p>&nbsp;</p><p><em>C</em><em>Y</em><em>P3A4 inducers</em></p><p>Lurasidone is contraindicated with strong CYP3A4 inducers (e.g. carbamazepine, phenobarbital, phenytoin, rifampicin, St John&rsquo;s wort (<em>Hypericum perforatum</em>)) (see section 4.3).</p><p>&nbsp;</p><p>Coadministration of lurasidone with the strong CYP3A4 inducer rifampicin resulted in a 6-fold decrease in exposure of lurasidone.</p><p>&nbsp;</p><p>Coadministration of lurasidone with mild (e.g. armodafinil, amprenavir, aprepitant, prednisone, rufinamide) or moderate (e.g. bosentan, efavirenz, etravirine, modafinil, nafcillin) inducers of CYP3A4 would be expected to give a &lt;2-fold reduction in lurasidone exposure during</p><p>co-administration and for up to 2 weeks after discontinuation of mild or moderate CYP3A4 inducers.</p><p>&nbsp;</p><p>When lurasidone is coadministered with mild or moderate CYP3A4 inducers, the efficacy of lurasidone needs to be carefully monitored and a dose adjustment may be needed.</p><p>&nbsp;</p><p><em>Transporters</em></p><p>Lurasidone is a substrate of P-gp and BCRP <em>in vitro </em>and the <em>in vivo </em>relevance of this is unclear. Coadministration of lurasidone with P-gp and BCRP inhibitors may increase exposure to lurasidone.</p><p>&nbsp;</p><p><u>Potential for lurasidone to affect other medicinal products</u></p><p>&nbsp;</p><p>Coadministration of lurasidone with midazolam, a sensitive CYP3A4 substrate, resulted in a &lt; 1.5-fold increase in midazolam exposure. Monitoring is recommended when lurasidone and CYP3A4</p><p>substrates known to have a narrow therapeutic index (e.g. astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil or ergot alkaloids [ergotamine, dihydroergotamine]) are coadministered.</p><p>&nbsp;</p><p>&nbsp;</p><p>Coadministration of lurasidone with digoxin (a P-gp substrate) did not increase the exposure to digoxin and only slightly increased Cmax (1.3 &ndash;fold) and therefore, it is considered that lurasidone can be coadministered with digoxin. Lurasidone is an <em>in vitro </em>inhibitor of the efflux transporter P-gp and the clinical relevance of intestinal P-gp inhibition cannot be excluded. Concomitant administration of the P-gp substrate dabigatran etexilate may result in increased dabigatran plasma concentrations.</p><p>&nbsp;</p><p>Lurasidone is an <em>in vitro </em>inhibitor of the efflux transporter BCRP and the clinical relevance of intestinal BCRP inhibition cannot be excluded. Concomitant administration of BCRP substrates may result in increases in the plasma concentrations of these substrates.</p><p>&nbsp;</p><p>Coadministration of lurasidone with lithium indicated that lithium had clinically negligible effects on the pharmacokinetics of lurasidone, therefore no dose adjustment of lurasidone is required when coadministered with lithium. Lurasidone does not impact concentrations of lithium.</p><p>&nbsp;</p><p>A clinical drug interaction study investigating the effect of coadministration of lurasidone on patients taking oral combination contraceptives including norgestimate and ethinyl estradiol, indicated that lurasidone had no clinically or statistically meaningful effects on the pharmacokinetics of the contraceptive or sex hormone binding globulin (SHBG) levels. Therefore, lurasidone can be coadministered with oral contraceptives.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.6&nbsp;&nbsp;&nbsp; Fertility, pregnancy and lactation</strong></p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of lurasidone in pregnant women. Animal studies are insufficient with respect to effects on pregnancy, embryonal/fetal development, parturition and postnatal development (see section 5.3). The potential risk for humans is unknown. Lurasidone should not be used during pregnancy unless clearly</p><p>necessary.</p><p>&nbsp;</p><p>Neonates exposed to antipsychotics (including lurasidone) during the third trimester are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborns should be monitored carefully.</p><p>&nbsp;</p><p><u>B</u><u>r</u><u>east-feeding</u></p><p>&nbsp;</p><p>Lurasidone was excreted in milk of rats during lactation (see section 5.3). It is not known whether lurasidone or its metabolites are excreted in human milk. Breast feeding in women receiving Latuda should be considered only if the potential benefit of treatment justifies the potential risk to the child.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Studies in animals have shown a number of effects on fertility, mainly related to prolactin increase, which are not considered to be relevant to human reproduction (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.7&nbsp;&nbsp;&nbsp; Effects on ability to drive and use machines</strong></p><p>&nbsp;</p><p>Lurasidone has minor influence on the ability to drive and use machines. Patients should be cautioned about operating hazardous machines, including motor vehicles, until they are reasonably certain that lurasidone does not affect them adversely (see section 4.8).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.8&nbsp;&nbsp;&nbsp; Undesirable effects</strong></p><p>&nbsp;</p><p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The safety of lurasidone has been evaluated at doses of 18.5 -148 mg in clinical studies in patients with schizophrenia treated for up to 52 weeks and in the post-marketing setting. The most common adverse drug reactions (ADRs) (&ge; 10%) were akathisia and somnolence, which were dose-related up to</p><p>111 mg daily.</p><p>&nbsp;</p><p><u>T</u><u>abulated summary of adverse reactions</u></p><p>&nbsp;</p><p>Adverse drug reactions (ADRs) based upon pooled data are shown by system, organ class and by preferred term are listed below. The incidence of ADRs reported in clinical trials is tabulated by frequency category. The following terms and frequencies are applied: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1000), very rare</p><p>(&lt;1 /10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong><u>T</u></strong><strong><u>able 1</u></strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p><strong>System Organ</strong></p><p><strong>Class</strong></p></td><td><p><strong>Very</strong></p><p><strong>Common</strong></p></td><td><strong>Common</strong></td><td><strong>Uncommon</strong></td><td><strong>Rare</strong></td><td><p><strong>Frequency not</strong></p><strong>known</strong></td></tr><tr><td><p>Infections and</p><p>infestations</p></td><td>&nbsp;</td><td>&nbsp;</td><td>Nasopharyngitis</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Blood and</p><p>lymphatic system disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>Eosinophilia</td><td><p>Leukopenia****</p><p>Neutropenia****</p><p>Anemia****</p></td></tr><tr><td><p>Immune system</p><p>disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>Hypersensitivity#</td></tr><tr><td><p>Metabolism and</p><p>nutrition disorders</p></td><td>&nbsp;</td><td><p>Weight</p><p>increased</p></td><td><p>Decreased appetite</p><p>Blood glucose increased</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Psychiatric</p><p>disorders</p></td><td>&nbsp;</td><td><p>Insomnia</p><p>Agitation Anxiety Restlessness</p></td><td><p>Nightmare</p><p>Catatonia</p></td><td>&nbsp;</td><td><p>Suicidal</p><p>behaviour****</p><p>Panic attack****</p><p>Sleep disorder****</p></td></tr><tr><td><p>Nervous system</p><p>disorders</p></td><td><p>Akathisia</p><p>Somnolence*</p></td><td><p>Parkinsonism**</p><p>Dizziness Dystonia*** Dyskinesia</p></td><td><p>Lethargy</p><p>Dysarthria Tardive dyskinesia</p></td><td><p>Neuroleptic</p>malignant syndrome (NMS)</td><td>Convulsion****</td></tr><tr><td>Eye disorders</td><td>&nbsp;</td><td>&nbsp;</td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Blurred vision</p></td><td>&nbsp;</td></tr></tbody></table></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Ear and</p><p>labyrinth disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>Vertigo****</td></tr><tr><td><p>Cardiac</p><p>disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Tachycardia</p></td><td>&nbsp;</td></tr></tbody></table></td><td>&nbsp;</td><td><p>Angina****</p>AV block first degree**** Bradycardia****</td></tr><tr><td><p>Vascular</p><p>disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Hypertension</p><p>Hypotension</p><p>Orthostatic hypotension Hot flush Blood pressure increased</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Gastrointestinal</p><p>disorders</p></td><td>&nbsp;</td></tr></tbody></table></td><td>&nbsp;</td><td><p>Nausea</p><p>Vomiting Dyspepsia Salivary hypersecretion Dry mouth Upper abdominal pain Stomach discomfort</p></td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Flatulence</p></td><td>&nbsp;</td></tr></tbody></table></td><td>&nbsp;</td><td><p>Diarrhoea****</p><p>Dysphagia****</p><p>Gastritis****</p></td></tr><tr><td><p>Hepatobiliary</p><p>disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Alanine</p>aminotransferase increased</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p><strong>System Organ</strong></p><p><strong>Class</strong></p></td><td><p><strong>Very</strong></p><p><strong>Common</strong></p></td><td><strong>Common</strong></td><td><strong>Uncommon</strong></td><td><strong>Rare</strong></td><td><strong>Frequency not known</strong></td></tr><tr><td><p>Skin and</p>subcutaneous tissue disorders</td><td>&nbsp;</td><td>&nbsp;</td><td>Hyperhidrosis</td><td>&nbsp;</td><td><p>Rash****</p><p>Pruritus****</p><p>Angioedema****</p><p>Stevens-Johnson syndrome</p></td></tr><tr><td><p>Musculoskeletal</p>and connective tissue disorders</td><td>&nbsp;</td><td><p>Musculoskeletal</p><p>stiffness&nbsp;Blood creatine phosphokinase increase</p></td><td><p>Joint stiffness</p><p>Myalgia</p><p>Neck pain</p><p>Back pain</p></td><td>Rhabdomyolysis</td><td>&nbsp;</td></tr><tr><td><p>Renal and</p>urinary disorders</td><td>&nbsp;</td><td><p>Serum&nbsp;creatinine increased</p></td><td>Dysuria</td><td>&nbsp;</td><td>Renal failure****</td></tr><tr><td><p>Pregnancy,</p>puerperium and perinatal conditions</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td><p>Drug withdrawal syndrome neonatal&nbsp;(see 4.6)</p></td></tr><tr><td><p>Reproductive&nbsp;system and breast disorders</p></td><td>&nbsp;</td><td>&nbsp;</td><td><p>Blood prolactin&nbsp;increased</p></td><td>&nbsp;</td><td><p>Breast</p><p>enlargement****</p><p>Breast pain****</p><p>Galactorrhoea****</p><p>Erectile dysfunction****</p><p>Amenorrhoea**** Dysmenorrhoea****</p></td></tr><tr><td><p>General&nbsp;disorders and administration site conditions</p></td><td>&nbsp;</td><td>Fatigue</td><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Gait disturbance</p></td></tr></tbody></table></td><td>&nbsp;</td><td><p>Sudden death attributable to underlying cardiovascular disease observed during the clinical</p>development programme****</td></tr></tbody></table><p>&nbsp;</p><p>*Somnolence includes adverse reaction terms: hypersomnia, hypersomnolence, sedation, and somnolence</p><p><br />**Parkinsonism includes adverse reaction terms: bradykinesia, cogwheel rigidity, drooling, extrapyramidal disorder, hypokinesia, muscle rigidity, parkinsonism, psychomotor retardation, and tremor</p><p>***Dystonia includes adverse reaction terms: dystonia, oculogyric crisis, oromandibular dystonia, tongue spasm, torticollis, and trismus.</p><p>****ADRs noted in Phase 2 and 3 controlled and uncontrolled studies; however, the incidence of occurrence for these</p><p>are too low to estimate frequencies.</p><p># Hypersensitivity may include symptoms such as throat swelling, tongue swelling, urticaria, or symptoms of angioedema, rash or pruritus (grouped under Skin and subcutaneous tissue disorders in Table 1).</p><p>&nbsp;</p><p><u>D</u><u>escription of selected adverse reactions</u></p><p>&nbsp;</p><p>Post marketing reports of clinically serious cases of skin and other hypersensitivity reactions have been reported in association with lurasidone treatment, including some reports of Stevens-Johnson syndrome.</p><p>&nbsp;</p><p><em>Events of interest to the class</em></p><p><em>Extrapyramidal symptoms (EPS)</em>: In the short-term placebo controlled studies, the incidence of reported events related to EPS, excluding akathisia and restlessness, was 13.5% for lurasidone-treated</p><p>subjects versus 5.8% for placebo-treated subjects. The incidence of akathisia for lurasidone-treated</p><p>subjects was 12.9% versus 3.0% for placebo-treated subjects.</p><p>&nbsp;</p><p><em>D</em><em>ystonia</em>: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of</p><p>&nbsp;</p><p>the neck muscles, sometimes progressing to tightness of the throat, difficulty swallowing, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity, higher potency and at higher doses of first generation antipsychotic medicinal products. An elevated risk of acute dystonia is observed in males and younger age groups.</p><p>&nbsp;</p><p><em>Venous thromboembolism</em>: Cases of venous thromboembolism, including cases of pulmonary embolism and cases of deep vein thrombosis have been reported with antipsychotic drugs -Frequency unknown.</p><p>&nbsp;</p><p><u>R</u><u>eporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in below:</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.9&nbsp;&nbsp;&nbsp; Overdose</strong></p><p>&nbsp;</p><p><u>Management of overdose</u></p><p>&nbsp;</p><p>There is no specific antidote to lurasidone, therefore, appropriate supportive measures should be instituted and close medical supervision and monitoring should continue until the patient recovers. Cardiovascular monitoring should commence immediately, including continuous electrocardiographic monitoring for possible arrhythmias. If antiarrhythmic therapy is administered, disopyramide, procainamide, and quinidine carry a theoretical hazard of QT-prolonging effects when administered in patients with an acute overdose of lurasidone. Similarly the alpha-blocking properties of bretylium might be additive to those of lurasidone, resulting in problematic hypotension.</p><p>&nbsp;</p><p>Hypotension and circulatory collapse should be treated with appropriate measures. Adrenaline and dopamine should not be used, or other sympathomimetics with beta agonist activity, since beta stimulation may worsen hypotension in the setting of lurasidone-induced alpha blockade. In case of severe extrapyramidal symptoms, anticholinergic medicinal products should be administered.</p><p>&nbsp;</p><p>Gastric lavage (after intubation if patient is unconscious) and administration of activated charcoal together with a laxative should be considered.</p><p>&nbsp;</p><p>The possibility of obtundation, seizures, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.1&nbsp;&nbsp;&nbsp; Pharmacodynamic properties</strong></p><p>&nbsp;</p><p>Pharmacotherapeutic group: Psycholeptics, antipsychotics. ATC code: N05AE05</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Lurasidone is a selective blocking agent of dopamine and monoamine effects. Lurasidone binds strongly to dopaminergic D2- and to serotonergic 5-HT2A and 5-HT7- receptors with high binding affinity of 0.994, 0.47 and 0.495 nM, respectively. It also blocks &alpha;2c-adrenergic receptors and</p><p>&alpha;2a-adrenergic receptors with a binding affinity of 10.8 and 40.7 nM respectively. Lurasidone also exhibits partial agonism at the 5HT-1A receptor with a binding affinity of 6.38 nM. Lurasidone does</p><p>not bind to histaminergic or muscarinic receptors.</p><p>&nbsp;</p><p>The mechanism of action of the minor active metabolite of lurasidone ID-14283 is similar to that of lurasidone.</p><p>&nbsp;</p><p>Lurasidone doses ranging from 9 to 74 mg (10-80 mg lurasidone hydrochloride) administered to healthy subjects produced a dose-dependent reduction in the binding of 11C-raclopride, a D2/D3 receptor ligand, in the caudate, putamen and ventral striatum detected by positron emission tomography.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>In the main clinical efficacy studies, lurasidone was administered at doses of 37-148 mg lurasidone</p><p>(equivalent to 40-160 mg lurasidone hydrochloride).</p><p>&nbsp;</p><p><em>C</em><em>li</em><em>n</em><em>i</em><em>cal efficacy</em></p><p>The efficacy of lurasidone in the treatment of schizophrenia was demonstrated in five multi-centre, placebo-controlled, double-blind, 6-week trials in subjects who met Diagnostic and Statistical Manual</p><p>of Mental Disorders, Fourth Edition (DSM-IV) criteria for schizophrenia. Lurasidone doses, which</p><p>varied across the five trials, ranged from 37 to 148 mg lurasidone (equivalent to 40-160 mg lurasidone hydrochloride) once daily. In the short-term trials, the primary efficacy endpoint was defined as the</p><p>mean change from baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) total scores,</p><p>a validated multi-item inventory composed of five factors to evaluate positive symptoms, negative symptoms, disorganised thoughts, uncontrolled hostility/excitement, and anxiety/depression. Lurasidone demonstrated superior efficacy compared with placebo across Phase 3 studies (see</p><p>Table 2). Lurasidone showed significant separation from placebo from as early as Day 4. Additionally, lurasidone was superior to placebo on the predefined secondary endpoint Clinical Global Impression &ndash; Severity (CGI-S) scale. Efficacy was also confirmed in a secondary analysis of treatment response (defined as &ge; 30% decrease from Baseline in PANSS total score).</p><p>&nbsp;</p><p><strong><u>T</u></strong><strong><u>able 2</u></strong></p><p><em>Schizophrenia Studies: Positive and Negative Syndrome Scale for Schizophrenia (PANSS) Total</em></p><p><em>Score - Change From Baseline to Week 6- MMRM for Studies D1050229, D1050231, and D1050233: Intent-to-Treat Analysis Set</em></p><table border="1" cellspacing="1" cellpadding="1" style="width:995px"><tbody><tr><td rowspan="2" colspan="1" style="width:150px"><strong>Study Statistic</strong></td><td rowspan="2" colspan="1" style="width:279px"><strong>Placebo</strong></td><td rowspan="1" colspan="4" style="width:432px"><strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Lurasidone dose (b) (c)</strong></td><td rowspan="2" colspan="1" style="width:131px"><strong>Active&nbsp;Control (a)</strong></td></tr><tr><td style="width:103px"><strong>37 mg</strong></td><td style="width:105px"><strong>74 mg</strong></td><td style="width:103px"><strong>111 mg</strong></td><td style="width:122px"><strong>148 mg</strong></td></tr><tr><td style="width:150px"><p>Study D1050229&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>(9.7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;--</p><p>Treatment Difference vs.&nbsp;&nbsp;&nbsp;placebo</p><p>Estimate (SE)</p><p>p-value&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="width:279px"><p>N=124&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>96.8 (11.1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>-17.0 (1.8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>&nbsp;</p><p>--</p><p>--&nbsp;&nbsp; &nbsp;</p></td><td style="width:103px"><p>N=121&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>96.5 (11.6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>-19.2 (1.7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>&nbsp;</p><p>-2.1 (2.5)</p><p>0.591</p></td><td style="width:105px"><p>N=118&nbsp;&nbsp;&nbsp;&nbsp;</p><p>96.0 (10.8)&nbsp;</p><p>-23.4 (1.8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>&nbsp;</p><p>-6.4 (2.5) &nbsp;</p><p>0.034&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; &nbsp;</p></td><td style="width:103px"><p>&nbsp;N=123&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p><p>&nbsp;96.0(9.7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;-20.5(1.8)&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;</p><p>-3.5 (2.5)</p><p>0.391&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p></td><td style="width:122px"><p>--</p><p>--</p><p>--</p><p>&nbsp;</p><p>--</p><p>--</p></td><td style="width:131px"><p>--</p><p>--</p><p>--</p><p>&nbsp;</p><p>--</p><p>--</p></td></tr><tr><td style="width:150px">Study D1050231</td><td style="width:279px">N=114</td><td style="width:103px">N=118</td><td style="width:105px">--&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td><td style="width:103px">N=118</td><td style="width:122px">--</td><td style="width:131px">N=121</td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:995px"><tbody><tr><td rowspan="2" colspan="1" style="width:163px"><strong>Study Statistic</strong></td><td rowspan="2" colspan="1" style="width:267px"><strong>Placebo</strong></td><td rowspan="1" colspan="4" style="width:432px"><strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Lurasidone dose (b) (c)</strong></td><td rowspan="2" colspan="1" style="width:131px"><strong>Active&nbsp;Control (a)</strong></td></tr><tr><td style="width:103px"><strong>37 mg</strong></td><td style="width:105px"><strong>74 mg</strong></td><td style="width:103px"><strong>111 mg</strong></td><td style="width:122px"><strong>148 mg</strong></td></tr><tr><td style="width:163px"><p>Baseline Mean(SD)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>LS Mean Change (SE) Treatment Difference vs. placebo</p><p>Estimate (SE)</p><p>p-value&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="width:267px"><p>95.8 (10.8)</p><p>&nbsp;</p><p>-16.0 (2.1)</p><p>&nbsp;</p><p>&nbsp;</p><p>--</p><p>--</p></td><td style="width:103px"><p>96.6 (10.7)</p><p>-25.7 (2.0)</p><p>&nbsp;</p><p>&nbsp;</p><p>-9.7 (2.9)</p><p>0.002</p></td><td style="width:105px"><p>--</p><p>--</p><p>&nbsp;</p><p>&nbsp;</p><p>--</p><p>--&nbsp; &nbsp;&nbsp; &nbsp;</p></td><td style="width:103px"><p>97.9 (11.3)</p><p>-23.6 (2.1)</p><p>&nbsp;</p><p>&nbsp;</p><p>-7.5 (3.0)</p><p>0.022&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p></td><td style="width:122px"><p>--</p><p>--</p><p>&nbsp;</p><p>&nbsp;</p><p>--</p><p>--</p></td><td style="width:131px"><p>96.3 (12.2)</p><p>-28.7 (1.9)</p><p>&nbsp;</p><p>&nbsp;</p><p>-12.6 (2.8)</p><p>&lt;0.001</p></td></tr><tr><td style="width:163px"><p>Study D1050233</p><p>Baseline Mean (SD) LS Mean Change (SE)</p><p>Treatment Difference vs. placebo</p><p>Estimate (SE)</p><p>&nbsp;p-value</p><p>&nbsp;</p></td><td style="width:267px"><p>N=120</p><p>96.6 (10.2)</p><p>-10.3 (1.8)</p><p>&nbsp;</p><p>&nbsp;</p><p>--</p>&nbsp; &nbsp;--</td><td style="width:103px"><p>--</p><p>--</p><p>--</p><p>&nbsp;</p><p>&nbsp;</p><p>--</p>--</td><td style="width:105px"><p>N=125</p><p>97.7 (9.7)</p><p>-22.2 (1.8)</p><p>&nbsp;</p><p>&nbsp;</p><p>-11.9 (2.6)</p>&lt;0.001&nbsp; &nbsp; &nbsp;&nbsp;</td><td style="width:103px"><p>--</p><p>--</p><p>--</p><p>&nbsp;</p><p>&nbsp;</p><p>--</p>&nbsp; &nbsp;--</td><td style="width:122px"><p>N=121</p><p>97.9 (11.8)</p><p>-26.5 (1.8)</p><p>&nbsp;</p><p>&nbsp;</p><p>-16.2 (2.5)</p>&lt;0.001</td><td style="width:131px"><p>N=116</p><p>97.7 (10.2)</p><p>-27.8 (1.8)</p><p>&nbsp;</p><p>&nbsp;</p><p>-17.5 (2.6)</p>&lt;0.001</td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><span style="text-align:unset">(a) Olanzapine 15 mg in Study D1050231, quetiapine extended-release (XR) 600 mg in Study D1050233.</span></p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><br />N is number of subjects per model estimate.</p><p>(b) p-values for lurasidone vs. placebo were adjusted for multiple comparisons. P-values for olanzapine and quetiapine XR vs. placebo were unadjusted.</p><p>(c) Lurasidone doses of 37, 74, 111 and 148 mg are equivalent to 40, 80, 120 and 160 mg amounts of lurasidone hydrochloride.</p><p>&nbsp;</p><p>In the short-term studies there was no consistent dose-response correlation observed.</p><p>&nbsp;</p><p>Long-term maintenance efficacy of lurasidone (37 to 148 mg lurasidone once daily (equivalent to</p><p>40 -160 mg lurasidone hydrochloride)) was demonstrated in a 12 month non-inferiority trial with quetiapine extended release (XR) (200 to 800 mg once daily). Lurasidone was non-inferior to quetiapine XR in time to relapse of schizophrenia. Lurasidone had a small increase from baseline to Month 12 in body weight and body mass index (Mean (SD): 0.73 (3.36) kg and 0.28 (1.17) kg/m2, respectively) compared to quetiapine XR (1.23 (4.56) kg and 0.45 (1.63) kg/m2, respectively). Overall, lurasidone had a negligible effect on weight and other metabolic parameters including total</p><p>cholesterol, triglycerides, and glucose levels.</p><p>&nbsp;</p><p>In a long-term safety study clinically stable patients were treated using 37 &ndash; 111 mg lurasidone (equivalent to 40 &ndash; 120 mg lurasidone hydrochloride) or risperidone 2 &ndash; 6 mg. In that study the rate of relapse over a 12-month period was 20% for lurasidone and 16% for risperidone. This difference neared, but did not reach, statistical significance.</p><p>&nbsp;</p><p>In a long-term trial designed to assess the maintenance of effect, lurasidone was more effective than placebo in maintaining symptom control and delaying relapse of schizophrenia. After having been treated for an acute episode and stabilized for a minimum of 12 weeks with lurasidone, patients were then randomised in a double-blind manner to either continue on lurasidone or on placebo until they experienced a relapse in schizophrenia symptoms. In the primary analysis of time to relapse in which patients that withdrew without relapse were censored at the time of withdrawal, patients on lurasidone showed a significantly longer time to relapse compared with patients on placebo (p=0.039). The Kaplan-Meier estimates of the probability of relapse at Week 28 were 42.2% for lurasidone and 51.2% for placebo. The probability of all-cause discontinuation at Week 28 were 58.2% for lurasidone and</p><p>69.9% for placebo (p=0.072).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with lurasidone in one or more subsets of the paediatric population in schizophrenia (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.2&nbsp;&nbsp;&nbsp; Pharmacokinetic properties</strong></p><p>&nbsp;</p><p><u>A</u><u>bsorption</u></p><p>&nbsp;</p><p>Lurasidone reaches peak serum concentrations in approximately 1-3 hours.</p><p>&nbsp;</p><p>In a food effect study, lurasidone mean Cmax and AUC increased approximately by 2-3-times and</p><p>1.5-2-times, respectively, when administered with food compared to the levels observed under fasting conditions.</p><p>&nbsp;</p><p><u>D</u><u>i</u><u>stribution</u></p><p>&nbsp;</p><p>Following administration of 37 mg of lurasidone (equivalent to 40 mg lurasidone hydrochloride), the mean approximate apparent volume of distribution was 6000 L. Lurasidone is highly bound (~99%) to serum proteins.</p><p>&nbsp;</p><p><u>B</u><u>i</u><u>otransformation</u></p><p>&nbsp;</p><p>Lurasidone is metabolised mainly via CYP3A4. The major biotransformation pathways are oxidative</p><p>N-dealkylation, hydroxylation of norbornane ring, and S-oxidation.</p><p>&nbsp;</p><p>Lurasidone is metabolised into two active metabolites (ID-14283 and ID-14326) and two non-active metabolites (ID-20219 and ID-20220). Lurasidone and its metabolites ID-14283, ID-14326, ID-20219 and ID-20220 correspond to approximately 11.4, 4.1, 0.4, 24 and 11% respectively, of serum radioactivity respectively.</p><p>&nbsp;</p><p>CYP3A4 is the major enzyme responsible for metabolism of the active metabolite ID-14283. Lurasidone and its active metabolite ID-14283 both contribute to the pharmacodynamic effect at the dopaminergic and serotonergic receptors.</p><p>&nbsp;</p><p>Based on <em>in vitro </em>studies lurasidone is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP4A11, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP2E1 enzymes.</p><p>&nbsp;</p><p><em>I</em><em>n vitro, </em>lurasidone demonstrated no direct, or weak inhibition (direct or time-dependent) (IC50&gt;5.9 &mu;M) of the enzymes cytochrome P450 (CYP)1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4. Based on this data, lurasidone is not expected to affect the pharmacokinetics of medicinal products that are substrates of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1. For administration of medicinal products that are substrates of CYP3A4 with a narrow therapeutic range, see section 4.5.</p><p>&nbsp;</p><p>Lurasidone is an <em>in vitro </em>substrate of the efflux transporters P-gp and BCRP. Lurasidone is not subject to active uptake transport by OATP1B1 or OATP1B3.</p><p>&nbsp;</p><p>Lurasidone is an inhibitor of P-gp, BCRP and OCT1 <em>in vitro </em>(see section 4.5). Lurasidone is not expected to have a clinically relevant inhibitory potential on transporters OATP1B1, OATP1B3, OCT2, OAT1, OAT3, MATE1, MATE2K or BSEP based on <em>in vitro </em>data.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Following administration of lurasidone, the elimination half-life was 20-40 hours. Following oral administration of a radiolabelled dose, approximately 67% dose was recovered in faeces and 19% in urine. Urine comprised mostly of a number of metabolites with minimal renal excretion of parent compound.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p>&nbsp;</p><p>The pharmacokinetics of lurasidone is dose-proportional within a total daily dose range of 18.5 mg to</p><p>148 mg (equivalent to 20 to 160 mg lurasidone hydrochloride). Steady-state concentrations of lurasidone are reached within 7 days of starting lurasidone.</p><p>&nbsp;</p><p><u>Pharmacokinetics in special patient groups:</u></p><p>&nbsp;</p><p><em>Elderly people</em></p><p>Limited data have been collected in healthy subjects &ge; 65 years. Of the data collected, similar exposure was obtained compared with subjects &lt; 65 years. However, an increase in exposure in elderly subjects may be expected for patients if they have impaired renal or hepatic function.</p><p>&nbsp;</p><p><em>H</em><em>epatic impairment</em></p><p>The serum concentrations of lurasidone are increased in healthy subjects with Child-Pugh Class A, B and C hepatic impairment with an increased exposure of 1.5-, 1.7- and 3-fold respectively.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>The serum concentrations of lurasidone are increased in healthy subjects with mild, moderate and severe renal impairment with an increased exposure of 1.5, 1.9 and 2.0-fold respectively. Subjects</p><p>with ESRD (CrCl&lt;15 ml/min) have not been investigated.</p><p>&nbsp;</p><p><em>G</em><em>ender</em></p><p>There were no clinically relevant differences between genders in the pharmacokinetics of lurasidone in a population pharmacokinetic analysis in patients with schizophrenia.</p><p>&nbsp;</p><p><em>Race</em></p><p>There were no clinically relevant differences in the pharmacokinetics of lurasidone in a population pharmacokinetic analysis in patients with schizophrenia. It was noted that Asian subjects had 1.5 fold increased exposure to lurasidone compared to Caucasian subjects.</p><p>&nbsp;</p><p><em>Smoking</em></p><p>Based on <em>in vitro </em>studies utilising human liver enzymes, lurasidone is not a substrate for CYP1A2;</p><p>smoking should, therefore, not have an effect on the pharmacokinetics of lurasidone.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The pharmacokinetics of lurasidone in paediatric patients was investigated in 49 children aged</p><p>6-12 years and 56 adolescents aged 13-17 years. Lurasidone was administered as lurasidone hydrochloride at daily doses of either 20, 40, 80, 120 mg (6-17 years) or 160 mg (10-17 years only) for 7 days. There was no clear correlation between obtained plasma exposure and age or body weight. The pharmacokinetics of lurasidone in paediatric patients aged 6&ndash;17 years was generally comparable to those observed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.3&nbsp;&nbsp;&nbsp; Preclinical safety data</strong></p><p>&nbsp;</p><p>Nonclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential. Major findings in repeat-dose toxicity studies of lurasidone were centrally-mediated endocrine changes resulting from serum prolactin elevations in rats, dogs and monkeys. High serum prolactin levels in long-term repeat-dose studies in female rats were associated with effects on bones, adrenal glands, and reproductive tissues. In a long-term dog repeat-dose study, high serum prolactin levels were associated with effects on male and female reproductive tissues.</p><p>&nbsp;</p><p>In rats, lurasidone had no effect on male and female reproduction at oral doses of 150 and 0.1 mg/kg/day lurasidone hydrochloride, respectively, or on early embryonic development at an oral dose of 15 mg/kg/day lurasidone hydrochloride.</p><p>&nbsp;</p><p>A fertility study in female rats resulted in prolonged estrous cycle and delayed copulation at &ge;1.5 mg/kg/day lurasidone hydrochloride, whilst the copulation and fertility indices, and the numbers of corpora lutea, implantations and live fetuses were decreased at 150 mg/kg/day lurasidone hydrochloride. These effects were due to the hyperprolactinemia following lurasidone treatment, affecting the estrous cycle and copulatory behaviour as well as the maintenance of corpus luteum of the female rats, resulting in a decrease in implantation and the number of live foetuses. These prolactin-related effects are not considered to be relevant to human reproduction.</p><p>&nbsp;</p><p>A single dose of 10 mg/kg lurasidone hydrochloride to pregnant rats resulted in fetal exposure. In a dose range finding study in pregnant rats, 150 mg/kg/day lurasidone hydrochloride caused fetal growth retardation without signs of teratogenicity. Lurasidone was not teratogenic in rats or rabbits at an exposure similar to or below the maximum recommended human dose (148 mg lurasidone equivalent to 160 mg lurasidone hydrochloride).</p><p>&nbsp;</p><p>Lurasidone was excreted in milk of rats during lactation.</p><p>&nbsp;</p><p>Lurasidone was not genotoxic in a battery of tests. Mammary gland and/or pituitary gland tumours were observed in the mouse and rat carcinogenicity studies and are most likely due to the increased blood prolactin levels. These findings are common in rodents treated with antipsychotic medicinal products with dopamine D2 blocking activity and are considered to be rodent-specific.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>C</u><u>ore</u></p><p>Mannitol (E 421) Starch, pregelatinised</p><p>Croscarmellose sodium (E468)</p><p>Hypromellose 2910 (E 464) Magnesium stearate (E 470b)</p><p>&nbsp;</p><p><u>T</u><u>ablet coating</u> Hypromellose 2910 (E 464) Titanium dioxide (E 171) Macrogol 8000</p><p>Carnauba wax (E 903)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>&nbsp;</p><p>Store in the original package in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cartons contain 28 tablets in aluminium/aluminium perforated unit dose blisters (2 blister strips, each containing 14 film coated tablets).</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sunovion Pharmaceuticals Europe Ltd. First Floor
Southside
97-105 Victoria Street
London SW1E 6QT United Kingdom

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                {03/2016}
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>